Dianthus Therapeutics (NASDAQ:DNTH) Shares Down 4.1%

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) fell 4.1% on Monday . The company traded as low as $24.75 and last traded at $24.75. 33,807 shares traded hands during trading, a decline of 77% from the average session volume of 144,789 shares. The stock had previously closed at $25.80.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. Raymond James upped their target price on Dianthus Therapeutics from $34.00 to $51.00 and gave the company an “outperform” rating in a report on Thursday, April 18th. Stifel Nicolaus initiated coverage on shares of Dianthus Therapeutics in a report on Thursday, February 15th. They issued a “buy” rating and a $44.00 price objective for the company. Jefferies Financial Group lifted their target price on shares of Dianthus Therapeutics from $22.00 to $39.00 and gave the stock a “buy” rating in a research note on Friday, March 22nd. Finally, Wedbush increased their price target on shares of Dianthus Therapeutics from $24.00 to $33.00 and gave the company an “outperform” rating in a research note on Friday, March 22nd. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $42.40.

Dianthus Therapeutics Trading Down 1.0 %

The firm has a fifty day simple moving average of $25.49 and a 200-day simple moving average of $18.22.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings results on Thursday, March 21st. The company reported ($0.71) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.11) by $0.40. The firm had revenue of $0.46 million for the quarter, compared to analysts’ expectations of $0.73 million. As a group, sell-side analysts forecast that Dianthus Therapeutics, Inc. will post -1.92 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Hussman Strategic Advisors Inc. acquired a new stake in shares of Dianthus Therapeutics during the first quarter worth about $630,000. Octagon Capital Advisors LP raised its stake in Dianthus Therapeutics by 15.4% during the 4th quarter. Octagon Capital Advisors LP now owns 554,000 shares of the company’s stock valued at $5,762,000 after acquiring an additional 74,000 shares during the last quarter. Vestal Point Capital LP acquired a new stake in Dianthus Therapeutics during the 4th quarter worth approximately $1,404,000. Tower Research Capital LLC TRC purchased a new position in shares of Dianthus Therapeutics in the 4th quarter valued at approximately $25,000. Finally, Citigroup Inc. acquired a new position in shares of Dianthus Therapeutics in the third quarter valued at approximately $53,000. 47.53% of the stock is owned by hedge funds and other institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.